Riccardo Lowi analyst at Capital Network talks through Evgen Pharma that has developed a proprietary technology - Sulforadex® - that allows the synthesis of sulforaphane in the form of a stable, solid powder that can be easily manufactured as an oral drug.
Riccardo Lowi discusses Evgen Pharma
Quick facts: Evgen Pharma PLC
Price: 3.25 GBX
Market Cap: £4.31 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE